Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic consequences for global human health and economics. Previously, we reached clinical evaluation with our vector vaccine based...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Proc Natl Acad Sci U S A
Autors principals: Tscherne, Alina, Schwarz, Jan Hendrik, Rohde, Cornelius, Kupke, Alexandra, Kalodimou, Georgia, Limpinsel, Leonard, Okba, Nisreen M. A., Bošnjak, Berislav, Sandrock, Inga, Odak, Ivan, Halwe, Sandro, Sauerhering, Lucie, Brosinski, Katrin, Liangliang, Nan, Duell, Elke, Jany, Sylvia, Freudenstein, Astrid, Schmidt, Jörg, Werner, Anke, Gellhorn Serra, Michelle, Klüver, Michael, Guggemos, Wolfgang, Seilmaier, Michael, Wendtner, Clemens-Martin, Förster, Reinhold, Haagmans, Bart L., Becker, Stephan, Sutter, Gerd, Volz, Asisa
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2021
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285915/
https://ncbi.nlm.nih.gov/pubmed/34162739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2026207118
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars